Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583 590. doi: 10.1161/01. CIR.0000154542.13412.B1. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, J rgensen CH, Lange T, Abildstr m SZ, Schramm TK, Vaag A, K ber L, Torp-Pedersen C, Gislason GH. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53:2546 2553. doi: 10.1007/s00125-010-1906-6. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010;16:200 206. doi: 10.1016/j.cardfail.2009.10.022. 143. Romero SP, Andrey JL, Garcia-Egido A, Escobar MA, Perez V, Corzo R, Garcia-Domiguez GJ, Gomez F. Metformin therapy and progno- sis of patients with heart failure and new-onset diabetes mellitus: a propensity-matched study in the community. Int J Cardiol. 2013;166:404 412. doi: 10.1016/j.ijcard.2011.10.141. 144. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, Struthers AD, Wong AK, Lang CC. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mel- litus. Am J Cardiol. 2010;106:1006 1010. doi: 10.1016/j. amjcard.2010.05.031. 145. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with di- abetes and atherothrombosis. Arch Intern Med. 2010;170:1892 1899. doi: 10.1001/archinternmed.2010.409. 146. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R, Lefer DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403 411. doi: 10.1161/CIRCRESAHA.108.190918. 147. 